Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Gonadal and Placental Hormones01:24

Gonadal and Placental Hormones

The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men.

Andrology·2019
Same author

Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.

Andrology·2018
Same author

Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive.

Andrology·2016
Same author

[Ischemic burden vs. coronary artery morphology : What is crucial for the indication of revascularization?].

Herz·2016
Same author

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.

Prostate cancer and prostatic diseases·2015
Same author

Humanin protects against chemotherapy-induced stage-specific male germ cell apoptosis in rats.

Andrology·2015

Related Experiment Video

Updated: Jun 23, 2026

Dual Somatic Recordings from Gonadotropin-Releasing Hormone (GnRH) Neurons Identified by Green Fluorescent Protein (GFP) in Hypothalamic Slices
09:30

Dual Somatic Recordings from Gonadotropin-Releasing Hormone (GnRH) Neurons Identified by Green Fluorescent Protein (GFP) in Hypothalamic Slices

Published on: February 24, 2010

Superactive gonadotropin-releasing hormone agonists.

R S Swerdloff, D Heber

    Annual Review of Medicine
    |January 1, 1983
    PubMed
    Summary

    Superactive Gonadotropin-releasing hormone (GnRH) agonists are new drugs that stop reproductive functions. They show promise for male and female contraception, prostate cancer, and other hormone-related conditions.

    Keywords:
    AcneBiologyContraceptionContraception ResearchEndocrine SystemEndometrial EffectsFamily PlanningFemale ContraceptionFollicle Stimulating HormoneGonadotropins--therapeutic useHirsutismHormones--therapeutic useLuteinizing HormoneMale ContraceptionPhysiologyPituitary Hormone Releasing Hormones--therapeutic useTestosterone

    More Related Videos

    In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
    10:36

    In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

    Published on: March 21, 2017

    Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
    04:37

    Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

    Published on: May 12, 2019

    Related Experiment Videos

    Last Updated: Jun 23, 2026

    Dual Somatic Recordings from Gonadotropin-Releasing Hormone (GnRH) Neurons Identified by Green Fluorescent Protein (GFP) in Hypothalamic Slices
    09:30

    Dual Somatic Recordings from Gonadotropin-Releasing Hormone (GnRH) Neurons Identified by Green Fluorescent Protein (GFP) in Hypothalamic Slices

    Published on: February 24, 2010

    In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
    10:36

    In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

    Published on: March 21, 2017

    Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
    04:37

    Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

    Published on: May 12, 2019

    Area of Science:

    • Reproductive endocrinology
    • Pharmacology

    Background:

    • Superactive Gonadotropin-releasing hormone (GnRH) agonists are a novel class of drugs.
    • These agents chronically inhibit reproductive functions in both sexes.

    Purpose of the Study:

    • To review the effects of GnRH agonists on reproductive hormones.
    • To assess the clinical potential of GnRH agonists for various conditions.

    Main Methods:

    • Review of existing literature on GnRH agonists.
    • Analysis of hormonal secretion data (gonadotropins and steroids).

    Main Results:

    • GnRH agonists suppress gonadotropin and steroid hormone secretion.
    • Demonstrated efficacy in preclinical and clinical studies for various applications.

    Conclusions:

    • GnRH agonists offer a promising therapeutic strategy for contraception, hormone-dependent cancers, and other endocrine disorders.
    • Further research is warranted to fully elucidate their long-term effects and optimize clinical applications.